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Summary 
An adequate assessment of the measurement uncertainty in
a laboratory medicine is one of the most important factors
for a reliable interpretation of the results. A large number of
standards and guidelines indicate the need for a proper
assessment of the uncertainty of measurement re sults in
routine laboratory practice. The available docu ments ge ne -
rally recommend participation in the proficiency schemes/
external quality control, as well as the internal quality control,
in order to primarily verify the quality performance of the
method. Although all documents meet the re quirements of
the International Standard, ISO 15189, the standard itself
does not clearly define the method by which the
measurement results need to be assessed and there is no
harmonization in practice regarding to this. Also, the
uncertainty of measurement results is the data relating to the
measured result itself, but all factors that influence the
interpretation of the measured value, which is ultimately
used for diagnosis and monitoring of the patient's treat ment,
should be taken into account. So in laboratory medicine, an
appropriate assessment of the uncertainty of the
measurement results should have the ultimate goal of
reducing diagnostic uncertainty. However, good profes sional
laboratory practice and understanding analytical aspects of
the test for each individual laboratory is ne ces sary to
adequately define the uncertainty of measurement results for
specific laboratory tests, which helps to imple ment good
clinical practice. Also, setting diagnoses in medicine is a
decision with a certain degree of uncertainty, rather than
statistically and mathematically calculated conclusion.
Keywords: ISO 15189, laboratory medicine, measure -
ment uncertainty
Kratak sadr`aj
Adekvatna procena nesigurnosti rezultata merenja u
biohemijskoj laboratoriji je jedan od najzna~ajnijih faktora
za pouzdanu interpretaciju rezultata. Veliki broj standarda i
vodi~a ukazuju na neophodnost pravilne procene nesigur -
nosti rezultata merenja u rutinskoj laboratorijskoj praksi.
Dostupni dokumenti uglavnom preporu~uju u~e{}e u {e -
mama osposobljenosti/spolja{njoj kontroli kvaliteta, kao i
svakodnevno merenje unutra{njih kontrola kvaliteta, kako
bi se primarno proverilo izvo|enje metode. Mada svi do -
kumenti zadovoljavaju zahteve internacionalnog standarda
ISO 15189, sam standard ne defini{e jasno metodu kojom
treba procenjivati nesigurnost rezultata merenja i ne postoji
harmonizacija u praksi. Tako|e, nesigurnost rezultata me -
renja je podatak koji se odnosi na sam izmereni rezultat, ali
treba uzeti u obzir sve faktore koji uti~u i na interpretaciju
izmerene vrednosti, koja se u krajnjem koristi za dijagnozu
i pra}enje le~enja pacijenta. Tako da u laboratorijskoj me -
dicini odgovaraju}a procena nesigurnosti rezultata merenja
treba da ima za krajnji cilj smanjenje dijagnosti~ke ne si -
gurnosti. Ipak, dobra profesionalna laboratorijska praksa i
razumevanje analiti~kih aspekata testa za svaku poje di -
na~nu laboratoriju je neophodno da bi se adekvatno defi -
nisala procena nesigurnosti rezultata merenja za specifi~na
laboratorijska ispitivanja, ~ime se poma`e sprovo|enje
dobre klini~ke prakse. Tako|e, postavljanje dijagnoze u
medicini je dono{enje odluke sa odre|enim stepenom
nesigurnosti, pre nego statisti~ki i matemati~ki prora~unat
zaklju~ak.
Klju~ne re~i: ISO 15189, laboratorijska medicina,
nesigurnost merenja
280 Milinkovi} et al.: Uncertainty of measurement in laboratory
Evolution of the concept of 
measurement uncertainty
Measurement uncertainty is a metrological con -
cept that is used to objectively evaluate the quality of
measurement results. The idea of measurement un -
certainty dates back to the 16th century, when scientists
from various applied sciences (astronomy, geodesy,
experimental physiology, genetics and sociology) wanted
to show the quality of the results of their measurements.
They mostly changed the measurement conditions and
monitored the influence of various factors leading to the
final measurement result, which led to the development
of the concept of mathematical modeling of these
factors in order to assess the measurement uncertainty
of the results (MU) (1–3).
The introduction of the concept of MU in
routine laboratory practice began only in the 80s of
the last century (4). Due to the lack of consensus in
the international scientific community on expressing
the uncertainty of measurement, the International
Bu reau for Weights and Measures (Bureau Inter na -
tional des Poids et Mesures, BIPM) established a
working group aimed at writing recommendations on
expressing measurement uncertainty (4). The do cu ment
»Recommendation INC-1 – Expression of Expe rimen -
tal Uncertainty« was approved by the International
Com mittee for Weights and Measures (Comité In ter na -
 tional des Poids et Mesures, CIPM) (5). CIPM sug gests
that the International Organi zation for Stan dar di za -
tion (ISO) develops a master document for measure -
ment uncertainty based on the recommen da tions of
the BIPM working group. The ISO Techni cal Advisory
Group for Metrology (TAG 4) was responsible for
writing a guide, with seven organi za tions from various
fields participating: BIPM, International Electro -
technical Commission (IEC), ISO, International Orga -
ni zation of Legal Metrology, OIML), the International
Union of Pure and Applied Chemistry (IUPAC), the
International Union of Pure and Applied Physics
(IUPAP) and the International Federation of Clinical
Chemistry and Laboratory Me dicine (IFCC), a repre -
sentative for medical labora tories. TAG 4 defined
Workgroup 3 (ISO/TAG 4/WG 3) with a panel of
experts from BIPM, OIML, IEC and ISO. The Guide to
the Expression of Uncertainty in Measurement (GUM)
was first published in 1993, and two years later
corrected and re-printed. Since 2008, when BIPM re-
published the corrected edition of the original
document, the GUM can be down loaded free of
charge from the BIPM website (6).
It is important to note that the terminology used
in the GUM document on the assessment of measu -
rement uncertainty was taken from the International
Vocabulary of Metrology (VIM), which is also avail -
able on the BIPM website (7). However, the inter -
pretation of this dictionary is, until now, the main
problem in the proper application and assessment of
MU in routine laboratory diagnostics.
According to the VIM document, MU is »not a
negative parameter that characterizes the dissipation
of quantitative values attributable to the measured
component, based on the information used« (section
2.26) (7). In laboratory medicine, it is accepted that
the MU parameter is associated with the result of
measurement, which is characterized by the dis si -
pation of a value that could reasonably be attributed
to the measured component, i.e. the analyte to be
determined (6). MU is the data that ensures the
reliability of the result itself. Reliability of the results is
necessary in situations where clinically significant
decisions are made and represent a quantitative
suspicion to the final outcome.
The most frequently numerically represented
MU is the measured value ± extended uncertainty, U.
Extended uncertainty is the interval in which the result
is expected, with a certain degree of confidence
(Confidence interval, CI). This is the product of the
standard combined uncertainty of u (uc) and the
coverage factor k. The choice of the numerical value
of the coverage factor depends on the desired
reliability with which the MU should be presented. For
CI approximately 95%, a coverage factor of 2 corre -
sponds, and for a CI greater than 99%, k is usually 3,
where the degrees of freedom for uc are greater than
20.
In clinical chemistry and laboratory medicine,
MU assessment is required as a mandatory/optional
item in accordance with ISO 17025 (General
Require ments for the Competence of Laboratory for
Testing and Calibration) and ISO 15189 (Special
Requirements for the Quality and Competence of
Medical Laboratories), original and supplementary
editions (2, 3). The first edition for the ISO 17025
standard was published in 1999, the supplementary
edition was published in 2005 (translation of this
standard into Serbian – SRPS ISO/IEC 17025:2005).
The first edition of the ISO 15189 standard was
published in 2003, and the supplementary editions
were subsequently published in 2007 and 2012 (the
translation of the latest supplemented standard into
Serbian – SRPS ISO 15189:2014).
Models for calculating the measurement
uncertainty of the results
The literature data point to two general models
that can be used to evaluate the MU: the original
bottom-up model based on the recommendations of
the GUM document and the phenomenologically top-
down model based on quality control data.
Bottom-up model
The only normative document, which is also
considered a »bible of uncertainty«, is the GUM do -
cument. Theoretical modeling relies on the principles
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of the original document published in 1980 (4). The
basic principles explained in this document are as
follows:
– The uncertainty of the result of a measure -
ment consists of several components, which
can be grouped into two categories according
to the way in which their numerical value is
estimated:
Components that are assessed by statistical
methods (Type A),
Components that are assessed by other means
(Type B).
– Classification in these two categories is not
always simple, so components are usually
defined as random and systemic uncertainties.
The concept of systemic uncertainty should be
avoided, as it may be misinterpreted. Each
detailed uncertainty report should contain a
complete list of components and in particular
emphasize the method by which the numerical
value of the uncertainty for each component
are obtained:
– Components belonging to Type A can be
represented by estimated variations (or esti -
mated standard deviation, SD) and number of
de grees of freedom, v. Where appropriate,
cova riances should also be indicated.
– The components belonging to Type B can be
presented as quantitative values (which
roughly explain the assumed variations).
Quantita tive values can be treated as varia -
tions and as SD. In the same way, covariances
should also be treated.
– Combined uncertainty should be displayed as
a numerical value obtained by applying the
usual method of combining variations. Com -
bined uncertainty and its components should
be expressed as standard deviations.
– If it is necessary to show the overall un -
certainty, the combined uncertainty should be
multiplied by the factor, which should be
clearly indicated, and it is designated as
extended uncertainty (4).
Specified principles provide a methodology in
which:
– An uncertainty assessment should include a
combination of major sources of uncertainty
– Uncertainties for random and systemic error
components should be treated as equal
– Uncertainty components are expressed as
combined standard uncertainty or extended
uncertainty (8). 
The approach proposed by the GUM document
is based on a model that is designed to understand
the interconnection of all sources of uncertainty that
significantly affect the result. Significant systemic
errors should be corrected and should not be taken
into account when calculating uncertainties. All major
sources that lead to the spread of uncertainty are
combined and the presented uncertainty is the
combined uncertainty ± the quantitatively presented
measured value.
This so-called up model (bottom-up model),
which the GUM suggests, is in function of various
inputs, i.e. factors leading to the final MU, i.e. has a
very large budget of uncertainty (a list of factors
leading to MU) (9). It is necessary to define a large
number of variations and covariances and use com -
plex mathematical modeling, so it is not suitable for
use in routine laboratory medicine. Also, the effort
and cost of assessing the uncertainty of the measure -
ment results should be proportional to the required
clinical quality of measurement (10).
The GUM document presents general rules for
assessing and expressing uncertainties in measure -
ment, rather than detailed technological-specific
instructions (6). Although the principles of this do -
cument are applicable to measurements in biology
and chemistry, they were initially valid for measure -
ments in mathematics and physics. The document
does not explain how an evaluated MU can be used
to match the result obtained with other similar results,
how to determine the limit of tolerance in the work
process and assess what corrective actions should be
taken.
Because of all the previously mentioned, the
GUM document indicates that specific standards
based on the GUM document (6) should be de -
veloped for each specific area. These standards
should be a simplified version of the original GUM
document, but contain details that correspond to the
level of accuracy and complexity of the corresponding
measurement.
Top-down model
Laboratory diagnostics is a medical discipline
that plays an important role in diagnosis, risk
assessment, treatment and monitoring of the patient.
Therefore, in laboratory medicine, precise and
accurate routine measurements are needed, which
ensure the reliability of the measurement result itself,
and thus adequate management of the patient. There
are a large number of different pre-analytical,
analytical and post-analytical factors that influence
MU in routine laboratory diagnostics, so the practical
application of the GUM model is not possible.
In 2000, Eurachem/CITAC published the
Quantifying Uncertainty in Analytical Measurement
(QUAM) paper, and in 2012, a supplement for a
unique application for assessing measurement
uncertainty in chemistry (11). This document examines
the practical experience in assessing the uncertainty
of measurement in chemical laboratories, and
empha sizes the need to integrate procedures that
assess the uncertainty of measurement with measure -
ments of existing quality control carried out in labo -
ratories. In this way, the validation of the method in
the MU assessment was clearly enabled, and in full
compliance with the GUM document, which enabled
the empirical approach or the top-down model of the
MU assessment in the routine medical laboratories
(9).
The top-down model meets the need of che -
mical laboratories, but it is often of little use for
methods used in medical laboratories. Nevertheless,
the concept of a top-down model is in accordance
with ISO 17025 and ISO 15189 standards, so the
QUAM document is the appropriate reference for
supporting MU assessment in a routine medical
laboratory (11).
Nordic countries Technical report, NordTest TR
537 and ISO 11352 standard, which explains the
assessment of measurement uncertainty based on
validation and quality control data (ISO 11352 Water
Quality Estimation of Measurement Uncertainty
Based on Validation and Quality Control Data) explain
the phenomenological approach of the top-down
model in the MU assessment (12, 13).
In routine medical laboratories, the application
of a top-down model is possible provided all factors of
impact are known and covered, but also repre -
sentative for all measurements by the same method.
Two major impacts on measurement uncertainty in
routine medical laboratories are random and systemic
effects (14). These two types of effects can be pre -
sented within the intra-laboratory precision and the
residual bias of measurement, and are part of the
analytical error in the medical laboratory. A random
error is a measurement component that varies in an
unpredictable manner, while the systemic error
remains constant, but the change can be predicted
(14).
A top-down approach is practical for routine use,
but it can override a systemic error of determination.
Although this is considered to have no significant
impact on the accuracy of the method, since
commer cial methods of determination with the same
bias are used, in general. However, correction of the
systemic error is often necessary – not only when
using different methods, but also for estimating the
variation in the value of the blank test, the impact of
interference or incomplete recovery (15).
In this sense, it is necessary to display the
following steps for the top-down model:
– Clearly define which analyte is measured, in
which matrix, and by what method,
– Quantify the MU for the control sample (Type
A) (reproducibility within the laboratory, Rw)
and indicate potential impacts that are not
covered by the control sample,
– Quantify the bias for the method in the
laboratory,
– Display uncertainty components as standard
uncertainty (SD),
– Calculate the combined standard uncertainty
(uc, root from the sum of squares of individual
standard uncertainties),
– Calculate extended uncertainty (U = 2 x uc),
– Show extended uncertainty as ± _%.
If the control sample is unstable, reproducibility
can be achieved by analyzing the duplicate measure -
ment in a patient sample (12). The results of the
duplicate are analyzed and represented on the R map
(map for the range), to which the data of the differ -
ence of two measurements are entered directly. This
map can also be presented in the form of % of the
mean value for the analyzed pair of measurements in
one sample. This approach is useful when concen -
trations of the analyte vary in a lot of controls that
often change.
Total error concept
The concept of total error calculation (Total
Error, TE) was introduced in 1974, with the aim of
quantitative approach in assessing the acceptability of
the measurement procedure (16). TE represents the
expression of the overall deviation of the test result
from its exact value and is initially shown by the
following formula: TE = bias + z × CVa. The esti -
mation of the TE takes into account both random and
systemic errors: it means knowledge of the bias and
the analytical coefficient of variation (CVa). Bias is
calculated using the following formula:
Bias (%) = (x – y0)/y0 × 100
where x is the obtained value, and y0 is the
target value. CVa represents the percentage of the
standard deviation of the mean value of the result
(SD/x × 100). However, data for imprecision can be
used instead of CV data. The statistical z value is a
table number describing the level of reliability of the
result (which is usually about 95%) for a measurable
error, despite the remaining 5% chance that the test
result may exceed this limit.
A preferred total allowable analytical error (TEa)
in routine laboratory medicine can be calculated from
the following formulas:
TEa = Bias + 1.65 × imprecision
TEa = Bias + 1.65 × SD
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If the value is Z = 1.65, one-sided data
distribution with a CI of 95% is observed. For most
situations in routine work, the following formula
applies:
TEa < 0.25 × [CVi2 + CVg2]½ + z × 0.5 ×
CVi
where CVi is a variation within a person (intra-
individual variation), and CVg variations between
individuals (inter-individual variation) (17).
A critical error (Critical Error, CE) can also be
calculated based on the following formula (18):
DCE = [(TEa – Bias)/SD] – 1.65
The value of CE, i.e. changes of the TEa can be
used in the assessment of results and the selection of
appropriate quality control (QC or EQA).
The TE concept requires that the exact value of
the result should be known, because the error is
inherent in the measurement, otherwise TE cannot
be calculated (19). On the contrary, in the concept of
uncertainty of measurement, it is assumed that the
exact value of the result cannot be known. Unlike the
TE concept, when estimating the MU method, the
lack of accurate value of the results is underlined, with
the assertion that there is a lack of accurate know -
ledge of the true value of the result (14).
Literature data indicate that the imprecision of
the method as an indicator of random error of
determination is the main component of MU (20).
Also, if bias as an indicator of systemic error is not
negligible, i.e. clinically significant, can be removed
by correcting the analyte or recalibration. When bias
cannot be removed or treated as any other source of
uncertainty, it should be included in the calculation of
MU. If this is not possible, a medical laboratory may
display QC data and apply the TE concept to the MU
assessment (14).
Objectives in achieving measurement
uncertainty of the results
In routine medical laboratories, it is important to
set up and achieve appropriate goals for MU. This
means that the uncertainty of measurement is to give
the result and procedure within the clinically
acceptable limits, so that the results are of the appro -
priate quality and reliability for patient management.
Depending on the physiology of the analyte, the type
of sample and the clinical use of the determined re -
sults, the goals can be based on the biological varia -
tion or the recommendations and the professional
opinions of the experts. There are limitations in meeting
targets in relation to the measurement characteristics
of the procedures and the instruments on which the
analyte is measured, which should be taken into
account in the MU assessment. 
In order to achieve the objectives of MU it is
necessary to achieve traceability. According to the
VIM document, traceability is »Characteristic of
measurement results so that the result can be linked
to references through a documented continuous
calibration chain, each contributing to measurement
uncertainty« (7). Measurement uncertainty and bias
are determined according to the metrological chain
of traceability (9). Accuracy, laboratory accreditation
levels, and instability and material costs increase
significantly from medical laboratories to the top of
the hierarchy, from routine medical laboratories to the
International System of Units (SI). On the contrary,
the measurement uncertainty of bias, and the
availability of materials are reduced from the bottom
to the top. Due to the inaccessibility of reference
materials and methods, this traceability chain has not
been properly implemented in medical laboratories
(21). Medical traceability is difficult to achieve due to
the physico-chemical complexity of the samples in
which the analyte is determined, which mainly results
from intra- and inter-individual biological variations
(22).
Biological variability of the analyte
The biological variability of the analyte examined
in the samples of patients in laboratory medicine may
be related to:
– Variations during the course of life, resulting
from physiological changes, growth, aging,
preg nan cy, menopause, or some other normal
circumstances,
– Predictable cyclical variations, which can be
daily, monthly or seasonal,
– Random variations, which depend on the
individual homeostatic mechanisms of each
individual (20).
Sources of random variation that affect the
result of the analyte measured in the patient sample
are:
– Pre-analytical, which involve preparing a
patient, collecting and handling the sample,
– Analytical, which imply imprecision and bias,
– Biological, which are the most important, and
involve variation within the person.
In order to achieve the results of an appropriate
quality, all sources of variation need to be minimized
by properly assessing the biological variation com -
ponents (within and between individuals). In every day
laboratory work, the result of the required parameter
for a diagnostic purpose is usually compared to the
population reference interval or with the limit value
for the parameter itself. Therefore, it is necessary for
laboratories to maintain an appropriate, centered
distri bution of results and minimize analytical bias. In
the case of monitoring the results, when the succes -
sive results of the same analyte are examined, it is
necessary to minimize analytical imprecision as the
main source of variation in the laboratory (23).
In order to achieve the appropriate analytical
characteristics of the methods in routine laboratory
diagnostics, it is necessary to define and analyze the
desirable characteristics for imprecision and bias,
which presents random and systemic effects that have
an impact on MU.
Literary data defines three levels of analytical
goal for imprecision and analytical bias (17, 23–25).
– Imprecision
Optimal: CVa ≤ 0.25 × CVi (increases the
varia bility of the result by 3%)
Preferred: CVa ≤ 0.50 × CVi (increases the
varia bility of the result by 12%)
Minimum: CVa ≤ 0.75 × CVi (increases the
variability of the result by 25%)
– Bias
Optimal: Bias ≤ 0.125 (CVi2 + CVg2)1/2
(increases the score outside the reference range
by 3.3%)
Preferred: Bias ≤ 0.250 (CVi2 + CVg2)1/2
(increases the score outside the reference range
by 4.4%)
Minimum: Bias ≤ 0.375 (CVi2 + CVg2)1/2
(increases the score outside the reference range
by 5.7%)
In order to evaluate the characteristics of
analytical procedures in the laboratory, in addition to
calculating imprecision and bias, biological variability
data can be used to calculate the sigma metric, which
can predict for which tests it will be necessary to
implement a minimum quality control (26). The
following formula is used to calculate the sigma
metric:
r = (%TEa – %Bias)/ %CVa
Biological variability data can be used in the
assessment of a clinically significant change in two
consecutive results for the same analytic for the same
patient, by calculating the Reference Change Value,
RCV (27).
RCV = 21/2 × Z × [CVa2 + CVi2]1/2
The practical benefit of conventional population
reference values can be estimated by analyzing
biological variability data, i.e. by calculating the index
of individuality (II) for each analyte (23).
II = (CVa2 + CVi2)1/2 / CVg
≈ CVi / CVg (if CVa ≤ CVi)
The practical benefit of the reference values will
be greater for analytes that have low II (>1.4),
compared to those having large II (<0.6) (28).
Knowing the data for RCV and II is of great
importance for clinical classifications (diagnosis,
prognosis or monitoring of the patient). To monitor
the patient's condition, it is desirable that the analyte
has a lower RCV, which indicates a high sensitivity of
the test, and for the diagnosis it is desirable that the
analyte has a high II (23).
Also, biological variability data of the analyte
can also be used to determine the optimum sample
for analyzing a specific analyte, selecting the appro -
priate units and samples for displaying analytical
results, validating and verifying the method (23).
The most frequently used data for the preferred
characteristics for TE, imprecision and bias, calcu -
lated on the basis of intra- and inter-individual
biological variations, are free available and shown in
tabular form, although these values should be
updated over a specific time period (29).
Suggested practical models for 
assessing the uncertainty of 
measurement results
The main reasons why a routine medical
laboratory should assess the MU are:
– The need or requirement for the laboratory to
display the result with the calculated MU
values in order to achieve good laboratory
practice,
– The need or requirement of a medical labo -
ratory for accreditation (ISO 15189),
– Necessary re-accreditation.
It is also necessary that MU data be made
available by manufacturers of in vitro diagnostic de -
vices in order to provide guidance for measurement
uncertainty in their information documents (30).
According to Technical Report 1/2007 of the
European Federation of National Association for
Measuring, Testing and Analytical Laboratories
(EUROLAB), four main approaches for evaluation of
uncertainty in measurement, which meet the basic
principles of uncertainty, are proposed:
– Modeling,
– Validation in a single laboratory (which
includes Quality Control, QC),
– Inter-laboratory comparison,
– External quality control data, i.e. laboratory
scheme (External Quality Assessment, EQA /
Proficiency Testing, PT).
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The laboratory remains on the basis of its own
needs, selects and defines one of the mentioned
proposal approaches, which will be used in routine
work for the assessment of MU.
ISO 15189 standard about measurement
uncertainty of result
Specific requirements for the quality and compe -
tence of medical laboratories defined in the inter na -
tional standard ISO 15189 in chapter 5.5, which
relates to testing procedures in medical laboratories, in
section 5.5.1. explains the selection, validation and
verification of test procedures, under point 5.5.1.4
states that the laboratory is obliged to determine the
uncertainty of measurement for each phase of the
measurement procedure test, which serves to express
the quantity of the measured value in the sample of
the patient. The laboratory is required to define the
require ments for determining the measurement un -
certainty for each measurement procedure and
regularly re-evaluates the MU (3). This points to the
necessity of the dynamics of estimating measurement
uncertainty. The laboratory itself estimates the fre qu -
ency of the MU assessment in relation to the changes
that lead to measurement uncertainty.
In addition to general information on MU, there
are three notes to be considered in routine work:
– Note 1: Components that are relevant to
uncertainty are those that relate to the current
measurement process, starting with the
sample used in the measurement process and
ending with the display of the measured value.
– Note 2: Measurement uncertainty can be
calculated using the quantitative values
obtained by measuring control samples under
precisely determined conditions that include
the default routine changes for the standard
measurement procedure, e.g. change of lot of
the reagents or calibrators, different operators,
regular maintenance of the instrument.
– Note 3: Examples of the practical benefits of
estimating measurement uncertainty are the
confirmation that the measured values of
patients meet the quality objectives set by the
laboratory and can be meaningfully compared
with the previous value or with a clinically
significant value.
The laboratory shall take into account the
measurement uncertainty in the interpretation of the
measured result to the users. In cases where the
testing process involves measurement steps, but not a
measured value report, the laboratory should
calculate the uncertainty of each measurement step,
if they have an impact in assessing the reliability of
the test procedure or have an impact on the displayed
results.
ISO 15189:2012 is for the time being the last
updated standard, which is also the most important
document for defining the characteristics of quality
and competence of medical laboratories. This stan -
dard is a good guide to routine medical laboratories
that need to be accredited, re-accredited, but also to
reviewers who work with accreditation bodies (31).
However, after a thorough analysis of this document,
it is noticed that there is no clearly defined re -
commendation for a methodology for assessment of
the measurement uncertainty. Despite the binding
requirements for calculating measurement uncertainty
and the elapsed time of 24 years since the GUM has
published a guide to expressing measurement un cer -
tainty, practical application has not been successfully
adopted in medical laboratories, i.e. there is no har -
mo nization in practice (32, 33).
Systematization of measurement 
uncertainty in medical laboratories
Since the publication of the GUM document on
measurement uncertainty assessment, several dif fe -
rent attitudes have been developed in professional
scientific circles (34). There are two expert currents
that explain the importance of assessing the un -
 certainty of measuring and/or computing the TE in
order to present top quality characteristics and com -
petencies of medical laboratories. However, in routine
laboratory work, a practical and easy approach is
required, enabling the adoption of appropriate
clinical decisions. Complex modular approaches that
are explained in literature are usually useful for re -
agent manufacturers, while simple empirical models
are useful for medical laboratories (20). The results of
the Global Survey on Measurement Uncertainty,
conducted in 2015, indicate the following:
– Most laboratories use, calculate, evaluate and
display MU data,
– Most laboratories use a simple formula for
assessing MU: they duplicate the imprecision
of a method that is monitored over a specific
period of time. There is no dominant formula
for calculating MU and most of the respon -
dents do not know how to count it,
– A small number of laboratories show the
calculated value for MU next to the results of
the tests on the report, most labs do not show
routine MU data to clinicians,
– The practical benefit of the MU assessment is
reflected in the increase in the monitoring of
the method, the more frequent contact with
the manufacturers of the tests, the change in
the frequency of QC or the recalibration of the
method,
– Most laboratories think that clinicians use MU
data only once a year and that these data is
practically useless,
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– MU data are considered to have an almost
negligible impact on the outcome of the
patient,
– Some laboratories do not evaluate MU be -
cause ISO 15189 is not binding and the
regulations of their countries do not require an
estimate, i.e. it is up to the laboratory to
decide what to do or clinicians do not ask the
laboratory about the MU,
– Regulations and requirements for accredi -
tation are the main reasons that the laboratory
estimates MU, a very small number of labo -
ratories use this data due to their own practical
needs and demands of the clinician (35).
There are a number of guidelines and regu -
lations in the world that explain the importance of MU
assessment in medical laboratories and propose
different approaches (36–42). Most of these docu -
ments suggest a top-down model that implies the use
of biological variability data for the calculation of TEa
or one of the proposed practical models in routine
laboratory diagnostics (QC, EQA, inter-laboratory
comparison). For now, the only global guideline and
guidance for assessing MU in medical laboratories is
the CLSI C51-A document, which is not free
available. This is a newer version of CLSI EP 29-A
(20). Nevertheless, literary criticism suggests that
most of this document comments on the bottom-up
model explained in the GUM document (43). The
second part of this guide explains the use of QC data
for the MU assessment. However, the Finnish Institute
of Environment has provided a free program for
calculating MU based on the NordTest TR 537
principles (44).
Assessing the uncertainty of measurement in
one of the suggested ways, laboratories should
improve and demonstrate the characteristics of the
methodology they use to obtain the patient's result.
Nevertheless, data of pre-analytical errors, which are
significant for the patient's own outcome, are not
taken into account in the final assessment of MU.
Also, ISO is one of the members of the editorial board
of GUM and VIM documents, so that the principles to
be applied (propagating) rely on uncertainties in
measurement, rather than on the concept of TEa
(34).
The proposed model that would be easier to
understand in routine laboratories implies the calcu -
lation of TEa based on the following formula (45):
TEa = bias + k × uc
In addition to bias, the standard combined
uncertainty is multiplied by the corresponding factor
(extended uncertainty) for the individual outcome, i.e.
result (34). Although the calculation does not fully
follow the GUM principles, it agrees with the model
formula defined in part F.2.4.5 of this document: U +
b (6). The complementarity of the measurement
uncertainty assessment and calculation of the TEa
(46) is directly proposed in addition. However, in
practice, laboratories have a much more important
standardization in the implementation of good
laboratory practice than the monitoring of current
discussions on TEs and MUs, which are still not
harmonized in practice (47).
Assessment of diagnostic uncertainty
The ultimate outcome of a complex process in
routine medical laboratories is the result of an
appropriate quality, i.e. accurate result. MU is a data
that relates to the measurement result itself, but it
should take into account all the factors that influence
the interpretation of the measured value used for
diagnosis and monitoring of the patient's treatment. In
laboratory medicine, an appropriate MU asses sment
should have the ultimate goal of reducing diagnostic
uncertainty (48). Although the concept of error is more
practical for a routine laboratory pro cess, it covers only
part of a complex test chain in laboratory medicine.
The concept of uncertainty implies the likelihood of the
impact of pre-analytical, analytical, biological and post-
analytical causes on the outcome of laboratory me -
dicine, which is a cli ni cal response to the outcome.
Also, measurement errors are usually a wider set of
causes of measu re ment uncertainty (49). However,
accepting the concept of error and the concept of
measurement is a prerequisite for achieving appro -
priate quality characteristics that are the basis of good
laboratory practice and contributes to reducing
diagnostic un certainty.
The problem of applying this comprehensive
model in routine laboratory medicine is precisely the
complex calculation of the MU end-point and the
corresponding interpretation, for which knowledge in
mathematics and advanced statistics is needed. It is
considered that the measurement uncertainty
assessment should have a predictive value. Instead of
frequentist statistics and determining the frequency of
a certain value with previously defined statistical sig -
nificance, it is necessary to consider all the previous
factors, i.e. influences on measurement uncertainty
and on the basis of them are predicted by some
possible factors that were not taken into account by
the original assessment (48). Knowledge of bio -
logical, pre-analytical and post-analytical variation, as
well as analytical variation is necessary, so that proper
use of the concept of uncertainty can contribute to
the clinical benefit of measuring methods. Despite
the requirements for measurement uncertainty,
baseline data are used to determine the analytical
error, the question arises as to whether laboratories
can combine the concept of measurement un -
certainty and the overall error of determination in
their routine work, while respecting the necessary
dynamics of the MU assessment?
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Methods for calculating MU are not detailed in
the standards, accreditation bodies have accepted the
concept of error and measurement uncertainty. It is
on the laboratory that it defines which approach to
use in assessing and displaying the characteristics of
the quality of its routine work. Current approaches to
measurement uncertainty that use imprecision and
accuracy calculation using control samples and use of
EQA/PT data relate to the uncertainty of the result of
the control sample itself, i.e. uncertainty of the
method. In order to evaluate the MU of the patient
result it is necessary to use patient samples. In this
way, it could affect diagnostic uncertainty which is the
ultimate goal of laboratory medicine. The question
arises as to whether this is practically possible?
Conclusion
In scientific circles, there is still no final con -
clusion on the methodology for evaluation the un -
certainty in the measurement in laboratory medicine.
Currently, ISO is implementing a new project on a
practical guideline for assessing measurement uncer -
tainty in medical laboratories (ISO/NP TS 20914
Medical Laboratories – Practical Guide for the
measure ment of measurement uncertainty). Medical
laboratories remain to continue to implement the basic
principles of good laboratory practice, thus helping
each other to implement good clinical practice. Also,
setting diagnoses in medicine is a decision with a
certain degree of uncertainty, rather than statistically
and mathematically calculated conclusion.
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